Navigation Links
Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results
Date:5/4/2009

09 were $540,494, compared with $474,176 during the three month period ended March 31, 2008, an increase of 14.1%. This increase was primarily a result of an expansion of Senesco's human health programs, specifically the Company's multiple myeloma research program, which was partially offset by a decrease in the cost of Senesco's research agreement with the University of Waterloo due to the strengthening of the U.S. dollar against the Canadian dollar.

General and administrative expenses were $532,245 for the three month period ended March 31, 2009, compared with $876,966 during the three month period ended March 31, 2008, a decrease of 39.3%. This decrease was primarily due to a 76.2% reduction in stock-based compensation.

As of March 31, 2009, the Company had cash and investments in the amount of $2,677,581, and working capital of $2,594,256. Senesco estimates that such amount will cover its expenses for approximately the next four months from March 31, 2009.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricult
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
2. Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
3. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
6. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
7. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
8. Senesco Technologies to Present at BIO 2008 Business Forum
9. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
10. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
11. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... A recent study from researchers in Tasmania ... that those who took probiotics were able to run for ... showed that in extreme heat conditions, probiotics were able to ... acne treatment explains what this new discovery means for ... skin condition. , While researchers tote the benefits of ...
(Date:5/21/2013)... YORK , May 21, 2013  The Lindsley F. ... today that it is a Grand Challenges Explorations ... Gates Foundation .  Dr. Sara Lustigman , ... innovative global health and development research project, titled Innovative ...  These worms are needed to screen drugs to help ...
(Date:5/21/2013)... The congress of the ERA-EDTA (European Renal Association ... congress in Europe on nephrology ... Istanbul to share their knowledge ... have been presented: / (1) Gupta, A ... REDUCES ESA USE" By SFP-iron administration, the ...
(Date:5/21/2013)... As the R&D sector becomes increasingly ... industry to deliver better products, faster. Collaborations between ... often means turning big ideas into reality, within ... with Sensidose AB and Recipharm, is one example ... market sooner. The partnership resulted in the development ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2
... 4 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... vice president of research and development, is scheduled ... Biotechnology & Medical Technology,Conference on June 12 at ... at the,New York Palace Hotel in New York ...
... $90.7 million, up 18% from the prior year,s second ... quarter, - Earnings per share of $0.28, an increase of approximately 87% over last ... quarter,- Operating cash flow of $23.6 million (Year-to-date operating cash flow of ... $38.8 million),- Launch of eight new food and beverage and four new nutritional supplement ...
... Collegiate Inventors and Innovators Alliance (NCIIA) presents, ... discoveries for, nerve injuries, premature babies ... Mass., June 4 Today the NCIIA presented ... work in the field. The top winners in ...
Cached Biology Technology:Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference 2Martek Announces Second Quarter 2008 Financial Results 2Martek Announces Second Quarter 2008 Financial Results 3Martek Announces Second Quarter 2008 Financial Results 4Martek Announces Second Quarter 2008 Financial Results 5Martek Announces Second Quarter 2008 Financial Results 6Martek Announces Second Quarter 2008 Financial Results 7Martek Announces Second Quarter 2008 Financial Results 8Martek Announces Second Quarter 2008 Financial Results 9Martek Announces Second Quarter 2008 Financial Results 10Martek Announces Second Quarter 2008 Financial Results 11Martek Announces Second Quarter 2008 Financial Results 12The NCIIA Recognizes Collegiate Biomedical Engineering Innovations 2The NCIIA Recognizes Collegiate Biomedical Engineering Innovations 3
(Date:5/21/2013)... in pharmacies and health stores, phosphatidylserine is a ... soy. Proven to improve cognition and slow memory ... experiencing memory impairment. Now a team headed by ... Tel Aviv University,s Department of Human Molecular ... improves the functioning of genes involved in degenerative ...
(Date:5/21/2013)... The largest gathering of biomass experts , ... , When? 03-07 June 2013 ... scientific research, resource assessment, market and policy developments, manufacturing ... the world and benefiting from its 2013 edition from ... more than 60 countries, more than 240 plenary and ...
(Date:5/20/2013)... Minnesota Medical School researchers from the Masonic Cancer Center, ... Tumor Program, have developed a new mouse model of ... to discover new genes and gene pathways driving this ... week in the journal Nature Genetics . , ... lab of David Largaespada, Ph.D., professor in the Medical ...
Breaking Biology News(10 mins):Common food supplement fights degenerative brain disorders 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4U of M researchers develop model for better testing, targeting of MPNST 2
... for the first time have shown the earliest stages ... of bones, teeth and sea shells. They ... a three-dimensional image of the nanoparticles that form the ... understanding of the formation of bones, teeth and shells. ...
... the most common vaginal infection in US women of childbearing ... the normal balance of bacteria in the vagina is disrupted ... BV puts a woman at increased risk for a variety ... in understanding how it can be prevented. Vitamin D may ...
... Va.The SNM Clinical Trials Network, an initiative designed ... through the integration of imaging biomarkers into multi-center ... supporter. SNM, the world,s largest medical and ... Clinical Trials Network in late 2008 to facilitate ...
Cached Biology News:Focus on the formation of bones, teeth and shells 2Vitamin D insufficiency linked to bacterial vaginosis in pregnant women 2SNM's clinical trials network gains added support from industry leader 2
Form: Ready to use Applications: ELISA...
... Strips have hydrophobic plastic supports that ... contact with toxic/hazardous solutions. Paper segments on ... leach into solution. Complementary indicator charts provide ... graduated in 1pH units; In packs of ...
... Analyzer for General Chemistries, Specialty Chemistries, QC, Reagent Development, Pharmaceutical Development, Physician Owned Labs, Drugs ... user-selectable wavelengths. ... ... ...
... System creates isogenic cell lines all ... the protein of interest. This homogeneous ... In this experiment the coding sequence ... into pcDNA5/FRT and transfected into Flp-In-293 ...
Biology Products: